Stockscreener 앱 받기
31.70
2.14%
0.675
전일 마감가:
$31.02
열려 있는:
$29.99
하루 거래량:
220.54K
Relative Volume:
0.30
시가총액:
$1.81B
수익:
$205.63M
순이익/손실:
$40.57M
주가수익비율:
48.03
EPS:
0.6599
순현금흐름:
$52.37M
1주 성능:
-13.15%
1개월 성능:
-7.82%
6개월 성능:
+38.35%
1년 성능:
+283.57%
1일 변동 폭
$29.86
$31.77
1주일 범위
$29.86
$37.49
52주 변동 폭
$5.35
$40.22
Stoke Therapeutics Inc Stock (STOK) Company Profile
명칭
Stoke Therapeutics Inc
전화
781-430-8200
주소
45 WIGGINS AVENUE, BEDFORD, MA
Compare STOK vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
31.67 | 1.77B | 205.63M | 40.57M | 52.37M | 0.6599 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.54 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.00 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
680.44 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.02 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
281.47 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-24 | 개시 | Wolfe Research | Outperform |
| 2026-02-05 | 개시 | Guggenheim | Buy |
| 2026-01-05 | 재개 | Chardan Capital Markets | Buy |
| 2025-07-18 | 개시 | Jefferies | Buy |
| 2024-12-20 | 개시 | Chardan Capital Markets | Buy |
| 2024-10-14 | 재개 | Leerink Partners | Outperform |
| 2024-03-26 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-11-20 | 재개 | JP Morgan | Neutral |
| 2023-07-25 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-05-01 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2023-04-26 | 재개 | Canaccord Genuity | Buy |
| 2023-01-06 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2022-10-24 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2022-01-31 | 개시 | Jefferies | Buy |
| 2021-12-03 | 개시 | BofA Securities | Buy |
| 2021-11-22 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-05-18 | 개시 | UBS | Neutral |
| 2021-05-10 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-02-10 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2020-12-15 | 재개 | H.C. Wainwright | Buy |
| 2020-12-11 | 재확인 | Needham | Buy |
| 2020-10-23 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-09-29 | 재개 | JP Morgan | Neutral |
| 2020-09-29 | 개시 | Needham | Buy |
| 2019-12-18 | 개시 | Wedbush | Outperform |
| 2019-11-12 | 개시 | BTIG Research | Buy |
| 2019-10-25 | 개시 | H.C. Wainwright | Buy |
| 2019-07-15 | 개시 | Canaccord Genuity | Buy |
| 2019-07-15 | 개시 | Cowen | Outperform |
| 2019-07-15 | 개시 | Credit Suisse | Outperform |
| 2019-07-15 | 개시 | JP Morgan | Overweight |
모두보기
Stoke Therapeutics Inc 주식(STOK)의 최신 뉴스
Stoke Therapeutics earnings missed by $0.21, revenue fell short of estimates - Investing.com Canada
Stoke Therapeutics (NASDAQ: STOK) launches $150M ATM sales agreement with Cantor - Stock Titan
Stoke Therapeutics (STOK): Analyst Ratings and Price Target Upda - GuruFocus
Stoke Therapeutics (NASDAQ:STOK) Earns "Buy" Rating from Chardan Capital - MarketBeat
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Analysts Conflicted on These Healthcare Names: Stoke Therapeutics (STOK), NRX Pharmaceuticals (NRXP) and Airsculpt Technologies (AIRS) - The Globe and Mail
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)March 17, 2026 - BioSpace
Stoke Therapeutics (NASDAQ:STOK) What Triggered This Sudden Drop? - Kalkine Media
Stoke Therapeutics (STOK) Quarterly Losses Test Newly Profitable Trailing Earnings Narrative - simplywall.st
STOK: Wedbush Raises Price Target for Stoke Therapeutics | STOK Stock News - GuruFocus
Insider Selling: Stoke Therapeutics (NASDAQ:STOK) Director Sells 605 Shares of Stock - MarketBeat
Stoke Therapeutics (STOK) chief patient officer exercises 10,000 RSUs into shares - Stock Titan
Stoke Therapeutics (STOK) CFO exercises 14,750 RSUs, now holding 14,750 shares - Stock Titan
Stoke Therapeutics (NASDAQ: STOK) CMO exercises 33,850 RSUs - Stock Titan
Stoke Therapeutics (STOK) director adds 61,750 shares through RSU settlements - Stock Titan
Stoke Therapeutics (NASDAQ: STOK) counsel exercises 25,475 RSUs into shares - Stock Titan
Director at Stoke Therapeutics (STOK) sells 605 shares in plan trade - Stock Titan
Stoke Therapeutics (NASDAQ:STOK) Shares Gap Down on Disappointing Earnings - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Stock Price Expected to Rise, Wedbush Analyst Says - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Stock Price Expected to Rise, Needham & Company LLC Analyst Says - MarketBeat
Needham Raises Price Target for Stoke Therapeutics (STOK) to $40 | STOK Stock News - GuruFocus
Stoke Therapeutics 2025 10-K: Advancing RNA-Based Medicines with TANGO Platform for Genetic Diseases - Minichart
Decoding Stoke Therapeutics Inc (STOK): A Strategic SWOT Insight - GuruFocus
Why Stoke Therapeutics (STOK) Is Down 11.4% After NEJM Data on Dravet Syndrome DrugAnd What's Next - simplywall.st
Stoke Therapeutics (NASDAQ:STOK) Issues Earnings Results, Misses Expectations By $0.22 EPS - MarketBeat
Stoke Therapeutics (NASDAQ: STOK) outlines Dravet Phase 3 plan and $165M Biogen alliance - Stock Titan
Stoke Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Stoke Therapeutics Hits Day Low at $33 Amid Price Pressure - Markets Mojo
Granahan Investment Management LLC Sells 278,514 Shares of Stoke Therapeutics, Inc. $STOK - MarketBeat
Checkpoint Capital L.P. Takes Position in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics, Inc.Common Stock (NQ: STOK - The Chronicle-Journal
[144] Stoke Therapeutics, Inc. SEC Filing - Stock Titan
Stoke Therapeutics, Inc. Experiences Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo
Stoke Therapeutics (NASDAQ:STOK) Stock Price Down 6.6% Following Insider Selling - MarketBeat
Aug Weekly: Can Stoke Therapeutics Inc grow without external fundingMarket Growth Review & Stock Market Timing Techniques - baoquankhu1.vn
Insider Selling: Stoke Therapeutics (NASDAQ:STOK) Director Sells 33,243 Shares of Stock - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Insider Sells $174,200.00 in Stock - MarketBeat
Insider Sell: Adrian Krainer Sells 33,243 Shares of Stoke Therap - GuruFocus
Stoke Therapeutics Director Sells Over 33,000 Shares - TradingView
Stoke Therapeutics (STOK) chair exercises options, sells 4,355 shares under 10b5-1 plan - Stock Titan
Director at Stoke Therapeutics (STOK) sells 33K shares under 10b5-1 plan - Stock Titan
Stoke Earnings: Clinical Narrative Eclipses Financial Disclosure - Trefis
(STOK) Risk Channels and Responsive Allocation - Stock Traders Daily
Highs Report: Is Stoke Therapeutics Inc in a long term uptrendPortfolio Risk Report & Reliable Intraday Trade Alerts - baoquankhu1.vn
Cresset Asset Management LLC Invests $771,000 in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics stock hits 52-week high at 39.88 USD By Investing.com - Investing.com Canada
Morgan Stanley Smith Barney files Rule 144 notice listing 58,769 and 31,739 STOK shares (STOK) - Stock Titan
Stoke Therapeutics (NASDAQ:STOK) Hits New 52-Week HighStill a Buy? - MarketBeat
Stoke Therapeutics stock hits 52-week high at 39.88 USD - Investing.com
Stoke Therapeutics earnings in focus amid Dravet trial progress - Investing.com South Africa
Stoke Therapeutics earnings in focus amid Dravet trial progress By Investing.com - Investing.com India
Stoke Therapeutics Inc (STOK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.42%
1.08%
자본화:
|
볼륨(24시간):